The 2026 Nobel Prize in Physiology or Medicine was awarded on October 5 to American scientist Karl Deisseroth and German researchers Peter Hegemann and Georg Nagel for their pioneering work on optogenetics, a groundbreaking technique that uses light to control nerve cells in the brain. The Nobel Assembly at Sweden’s Karolinska Institute recognized their discoveries involving light-gated ion channels, which have opened new avenues for understanding brain function and neurological disorders.
Optogenetics allows researchers to switch specific nerve cells on or off in living brains by introducing light-sensitive proteins that react to pulses of light. This method has enabled scientists to precisely map neural circuits, linking particular brain cells to behaviors, memories, and diseases. The technique is regarded as transformative in neuroscience, shifting the field from static anatomical mapping to dynamic, functional understanding of how cells communicate and contribute to behavior and disease.
The origins of the discovery trace back to the early 1990s, when Hegemann, studying the green alga Chlamydomonas, hypothesized that a single protein acted as both a light receptor and an ion channel. Together with Nagel, he identified and characterized channelrhodopsins, proteins that open channels in cell membranes in response to blue light, allowing ion flow that generates electrical impulses. They demonstrated that cells engineered to express these proteins became light-sensitive.
Building on this, Deisseroth introduced the gene encoding channelrhodopsin into rat nerve cells, showing in 2005 that light could stimulate electrical activity in these cells. Two years later, he extended the approach to living mice by using optical fibers to deliver light pulses into the brain, enabling precise control of neuronal circuits. This innovation gave rise to the field of optogenetics, which has rapidly become a core tool in neuroscience laboratories worldwide.
The impact of optogenetics extends beyond basic research. It has facilitated detailed studies of brain disorders such as depression, anxiety, schizophrenia, Alzheimer’s disease, Parkinson’s disease, addiction, epilepsy, and autism spectrum disorders. By identifying the specific neurons involved in these conditions in animal models, scientists hope to uncover targeted therapeutic strategies.
Clinically, early applications include experimental therapies for blindness caused by retinitis pigmentosa. Researchers use optogenetics to stimulate surviving retinal cells by inserting light-sensitive proteins to partially restore vision in affected patients. Optogenetic approaches are also being explored to improve cochlear implants and to develop treatments for other neurological disorders, though these applications remain mostly in trial phases.
The three laureates, aged 54 (Deisseroth), 71 (Hegemann), and 73 (Nagel), will share a prize of 12 million Swedish kronor (approximately $1.2 million). Deisseroth, a psychiatrist and bioengineering professor at Stanford University and an investigator at the Howard Hughes Medical Institute, described the award as an unexpected honor. Hegemann is a professor of experimental biophysics at Humboldt University in Berlin, while Nagel is a biophysics professor at the University of Würzburg.
In remarks following the announcement, Nobel committee members highlighted how optogenetics has launched a new era in neuroscience, enabling unprecedented insight into the brain’s complexity. Researchers anticipate further advances in understanding brain function, as well as novel treatments for neurological diseases, driven by the foundational work of these three scientists. The prize marks the first of the annual Nobel awards announced this year, with other prizes forthcoming in physics, chemistry, literature, peace, and economics.